Trimetazidine

Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA) . Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

Product Specifications

CAS Number

[5011-34-7]

UNSPSC

12352005

Hazard Statement

H302, H314, H412

Target

Autophagy

Type

Reference compound

Related Pathways

Autophagy

Applications

Cancer-programmed cell death

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/trimetazidine.html

Purity

99.84

Solubility

DMSO : 116.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

COC1=CC=C(CN2CCNCC2)C(OC)=C1OC

Molecular Formula

C14H22N2O3

Molecular Weight

266.34

Precautions

H302, H314, H412

References & Citations

[1]Shenghu He, et al. Protective effects of trimetazidine against vascular endothelial cell injury induced by oxidation. Journal of Geriatric Cardiology, December 2008 , Vol 5 No 4.|[2]Kantor PF, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17;86 (5) :580-8.|[3]Jain S, et al. Trimetazidine exerts protection against increasing current electroshock seizure test in mice. Seizure. 2010 Jun;19 (5) :300-2.|[4]Chrusciel P, et al. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014 Jun;74 (9) :971-80.|[5]Hossain F, et al.Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res. 2015 Nov;3 (11) :1236-47.